EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

2017-09-04
Price :
Published : Sep-2017
No. of Pages : 50

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

Summary

Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining.

To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the diagnosed prevalent cases (symptomatic) as well as data for the severity segmentation of the diagnosed prevalent cases (symptomatic) from primary market research. In addition, the forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases (symptomatic) of hand OA will increase from 17,948,101 cases in 2016 to 20,413,591 cases in 2026 at an annual growth rate (AGR) of 1.37%, the diagnosed prevalent cases (symptomatic) of knee OA will increase from 15,235,201 cases in 2016 to 17,641,626 cases in 2026 at an AGR of 1.58%, and the diagnosed prevalent cases (symptomatic) of hip OA will increase from 3,361,141 cases in 2016 to 3,867,480 cases in 2026 at an AGR of 1.51%.

Scope

– The Osteoarthritis (OA) EpiCast Report provides an overview of the risk factors and global trends of hand OA, knee OA, and hip OA in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– It includes a 10-year epidemiological forecast for the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA segmented by age (beginning at 18 years and older) and sex in these markets. The diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA are further segmented by severity using Kellgren-Lawrence (KL) grading into mild (KL = 2), and moderate to severe (KL = 3 to 4).
– The OA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The OA EpiCast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global OA market.
– Quantify patient populations in the global OA market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for OA therapeutics in each of the markets covered.
– Understand magnitude of OA population by disease severity.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Company Profile: 23andMe

Company Profile: 23andMe Summary 23andMe is a personal genomics and biotechnology company that leverages machine learning technology to provide DNA analysis services. It also offers web-based interactive tools to individuals, helping them understand their own genetics information. Scope The report provides information and insights into 23andMe, including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into 23andMe's business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success ......
$350

Company Profile: Fitbit, Inc.

Company Profile: Fitbit, Inc. Summary Fitbit, Inc. (Fitbit) offers a range of connected health and fitness devices that monitors various health parameters like sleep duration, heart rate, BMI, calories burned, exercise routines, etc. Scope The report provides information and insights into Fitbit, Inc., including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into Fitbit business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success factors.......
$350

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – India

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in India. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of India. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

The State of the Microbiome

The State of the Microbiome Summary GlobalData's "The State of the Microbiome", report provides an assessment of how the pharmaceutical industry perceives the state of the microbiome, including the challenges associated with developing, launching, and manufacturing microbiome therapeutics as well as where opportunity remains to invest in the microbiome space. Scope - Microbiome investment - determine level of activity and investment in the development of microbiome therapeutics by therapy area - Identify the challenges associated with - Developing microbiome therapeutics - Launching microbiome therapeutics - Manufacturing microbiome therapeutics. Reasons to buy - Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with devel......
$1495

Rheumatoid Arthritis: Epidemiology Forecast to 2027

Rheumatoid Arthritis: Epidemiology Forecast to 2027 Summary Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life. GlobalData epidemiologists used sources that provided the diagnosed incidence, diagnosed prevalence, and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06. In 2......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2018

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informati......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Central Retinal Vein Occlusion Global Clinical Trials Review, H2, 2018

Central Retinal Vein Occlusion Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Central Retinal Vein Occlusion Global Clinical Trials Review, H2, 2018" provides an overview of Central Retinal Vein Occlusion clinical trials scenario. This report provides top line data relating to the clinical trials on Central Retinal Vein Occlusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's pro......
$2500

Brain Hemorrhage Global Clinical Trials Review, H2, 2018

Brain Hemorrhage Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Brain Hemorrhage Global Clinical Trials Review, H2, 2018" provides an overview of Brain Hemorrhage clinical trials scenario. This report provides top line data relating to the clinical trials on Brain Hemorrhage. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials databa......
$2500

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H2, 2018

Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Chemotherapy Induced Peripheral Neuropathy Global Clinical Trials Review, H2, 2018" provides an overview of Chemotherapy Induced Peripheral Neuropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Chemotherapy Induced Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Tr......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy